The pharmaceutical firm raises full-year revenue targets for AUSTEDO, AJOVY, and UZEDY after Q2 2026 performance beats expectations.
Teva Pharmaceutical Industries raised its 2026 revenue midpoint by $75 million, citing stronger-than-expected sales of its key drugs. The company now targets AUSTEDO revenue between $2.45 billion and $2.6 billion, and AJOVY revenue of $850 million to $870 million for the year.
In Q2 2026, AUSTEDO, AJOVY, and UZEDY all delivered robust performance, prompting the upward revision. Prior guidance had not been disclosed in detail, but management highlighted consistent growth in these products as a driver for the adjustment.
The announcement reflects confidence in Teva’s pipeline, though no immediate market reaction was specified in the earnings call.